September 2024
U.S. Medical Affairs Outsourcing Market (By Services: Medical Science Liaisons (MSLs), Medical Writing & Publishing, Medical Monitoring, Medical Information, Others; By Industry: Pharmaceutical, Biopharmaceutical, Medical Devices) - Regional Outlook and Forecast 2024 to 2033
The U.S. medical affairs outsourcing market size was exhibited at USD 546.9 million in 2023 and is projected to touch USD 1,087.6 million by 2033, registering a CAGR of 7.1% from 2024 to 2033.
Medical affairs is the department inside a pharmaceutical or medical device organization that informs healthcare professionals with reliable information. By using a technique called medical affairs outsourcing, patients, healthcare providers (HCPs), and governmental organizations may get deep knowledge of patient data as well as healthcare regulations and practices. The process of discovering and developing new drugs requires both money and time. It can take more than 10 to 15 years to complete the process from early discovery or design to development and regulatory approval. To ensure the quality and effectiveness of a drug substance, several testing services are needed. In order to cut costs and time, pharmaceutical and biotechnology companies choose to outsource their services to contract research organizations (CROs), which is predicted to accelerate the market's growth. The World Health Organization published statistics in 2019 showing an increase in the yearly number of clinical trials registered, from 3,344 in 2004 to 54,894 in 2018. The product’s efficiency and safety for human consumption is monitored by the outsourcing companies.
Report Coverage | Details |
Market Size in 2023 | USD 546.9 million |
Market Size by 2033 | USD 1,087.6 million |
Growth Rate from 2024 to 2033 | CAGR of 7.1% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered |
|
Driver:
Increase in the number of clinical trials
Increased prevalence of both communicable and non-communicable disorders
Technological advancement
Restraints:
An expensive investment in clinical trials and drug development
Opportunities:
Decreased access to healthcare professionals & institutions
Advancement in R&D
COVID-19 Impact
Nearly every industry has been negatively impacted by the worldwide pandemic, and it is expected that industrial growth would be affected over the projected period. Many regulatory and outsourcing teams are under pressure as a result of COVID-19. It has, however, also had a favorable effect on the bio/pharmaceutical outsourcing sector, as rising R&D activity demand is simultaneously driving up the need for medical affairs services. Due to the increasing demand, many CROs are concentrating on their outsourcing as well as other business operations. Medical IoT devices that reside with patients at home are increasingly used to enhance outpatient therapy, lower the number of follow-up visits, and even use these devices in an emergency. The expansion of the medical affairs outsourcing market is anticipated to be accelerated by the introduction of competitive pricing and value-based pricing models.
Based on Services, the U.S. medical affairs outsourcing market is segmented into medical science liaisons, medical writing & publishing, medical information, and medical monitoring. The medical science liaisons (MSLs) market is estimated to grow at the fastest pace throughout the projected period due to the growing demand for professional medical writing, publication, and service supply from small, mid-sized, and major healthcare organizations.
Medical Science Liaisons are doctorate- and advanced-degree-holding healthcare professionals who act as regional extensions of medical affairs departments. They connect with stakeholders and healthcare experts and respond to their clinical queries about drugs, technologies, and the disorders they treat.
U.S. Medical Affairs Outsourcing Market Revenue, By Services, 2020 - 2023 (USD Million)
By Services | 2020 | 2021 | 2022 | 2023 |
Medical Writing & Publishing | 141.5 | 154.4 | 169.8 | 182.7 |
Medical Monitoring | 40.6 | 44.2 | 48.6 | 52.1 |
Medical Science Liaisons | 90.9 | 98.9 | 108.3 | 116.0 |
Medical Information | 113.8 | 122.7 | 133.4 | 141.8 |
Others | 45.6 | 48.5 | 51.9 | 54.2 |
Based on Industry, the U.S. medical affairs outsourcing market is segmented into pharmaceutical, biopharmaceutical, and medical devices. The medical devices are further segmented into therapeutic medical devices and diagnostic medical devices Therapeutic medical devices include any equipment, apparatus, appliance, or other items that are meant to be used by humans for a therapeutic purpose. A reagent, calibrator, control material, kit, specimen receptacle, software, instrument, apparatus, equipment, or system that is used alone or in combination with other diagnostic items for in vitro application is known as an in vitro diagnostic medical device (IVD). In 2023, the pharmaceutical industry held the larger market share. The demand for medical affairs providers has risen as a result of numerous patent expirations, for the development of new patent drafts in the US. The requirement for medical affairs outsourcing services in the market is anticipated to increase as a result of the biopharma industry's increased focus on the basic operations associated with drug development. The pandemic is expected to have a long-term impact on the pharmaceutical business, which has been facing poor growth, delayed medication approvals, and insufficient pharma manufacturing supply chain.
U.S. Medical Affairs Outsourcing Market Revenue, By Industry, 2020 - 2023 (USD Million)
By Industry | 2020 | 2021 | 2022 | 2023 |
Pharmaceutical | 227.9 | 247.3 | 270.3 | 289.1 |
Biopharmaceutical | 57.7 | 62.8 | 68.8 | 73.8 |
Medical Devices | 146.8 | 158.7 | 172.8 | 184.0 |
Segments Covered in the Report
By Services
By Industry
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
September 2024
September 2024
February 2024
June 2024